Dementia

Franklin, IN

44 Dementia Trials near Franklin, IN

Power is an online platform that helps thousands of Dementia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Mobile Telehealth for Alzheimer's Disease

Indianapolis, Indiana
This trial tests if the Brain CareNotes app can reduce stress for unpaid caregivers of dementia patients and improve patient symptoms. The app provides practical advice, reminders, and emotional support to help caregivers manage their tasks.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

184 Participants Needed

Remternetug for Alzheimer's Disease

Indianapolis, Indiana
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

280 Participants Needed

Lecanemab for Alzheimer's Disease

Indianapolis, Indiana
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

43 Participants Needed

Gantenerumab for Alzheimer's Disease

Indianapolis, Indiana
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

280 Participants Needed

Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease

Indianapolis, Indiana
This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

197 Participants Needed

Disease-Modifying Drugs for Alzheimer's Disease

Indianapolis, Indiana
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

490 Participants Needed

JNJ-63733657 for Alzheimer's Disease

Indianapolis, Indiana
This trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 80

523 Participants Needed

Virtual Support Program for Dementia

Indianapolis, Indiana
This trial involves frequent online meetings with nurses or social workers to help patients with dementia and their caregivers. The care coordinators assess needs and provide support to manage symptoms, stress, medications, other health issues, and future care planning.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

860 Participants Needed

PDM Alert for Postoperative Delirium

Indianapolis, Indiana
This study will be a pilot randomized controlled trial that will determine the effect of an indicator of delirium risk, which will be delivered either via a paper form or via the electronic medical record, on (1)postoperative delirium incidence; and (2)the development of long term cognitive decline and dementia.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

60 Participants Needed

Non-Contact Sleep Monitor for Alzheimer's Disease

Indianapolis, Indiana
This study seeks to evaluate the utility and efficacy of the Non-Contact Sleep Quality Monitor System when used to monitor the sleep quality of individuals living in long-term care (LTC) with either Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementia (ADRD). This before-after comparison trial will be conducted in several LTC facilities to evaluate the effect access to System Sleep Quality Data has on documentation of sleep disorders or treatments and sleep quality change over time for AD/ADRD participants in the intervention group as compared to the control group. All subjects will undergo sleep quality monitoring for 4-weeks. At the end of the first 2-weeks, research staff and LTC facility staff and medical providers will receive access to sleep monitoring data. We hypothesize that when real-time System Sleep Data is shared with LTC staff or healthcare providers, that sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality and decreasing daytime physical inactivity.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

100 Participants Needed

Deprescribing for Dementia

Indianapolis, Indiana
A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+

344 Participants Needed

Patient Priorities Care for Dementia

Indianapolis, Indiana
The goal of this pragmatic, embedded clinical trial is to analyze the implementation of Patient Priorities Care in primary care and geriatrics clinics with patients living with dementia or mild cognitive impairment. This study aims are: * demonstrate the feasibility of using the electronic health record to identify a diverse cohort of eligible patient and patient-care partner dyads who will engage in a Patient Priorities Care conversation with a trained facilitator. * demonstrate feasibility of pragmatically assessing clinical outcomes using the electronic health record, including a) number of days at home, b) total medications, and c) new referrals to specialist physicians. * examine key feasibility measures across racial, ethnic, and socioeconomic subgroups. Participants will receive a packet of information about Patient Priorities Care from their primary care clinic, in advance of their next upcoming clinic appointment. Individuals who receive a packet will have the opportunity to engage in a conversation about what matters most to them and what their priorities are, with trained facilitators at the clinic.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+

173 Participants Needed

AVP-786 for Agitation in Alzheimer's Disease

Indianapolis, Indiana
This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50 - 90

1197 Participants Needed

Palliative Care Program for Alzheimer's Disease

Indianapolis, Indiana
Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical, emotional and financial strain for caregivers. Investigators now propose a multi-site randomized clinical trial of the ADRD Palliative Care (ADRD-PC) program for persons with late-stage ADRD and their family caregivers, triggered during hospitalization. Investigators aim to learn if this program of dementia-specific palliative care, standardized caregiver education, and transitional care is effective to reduce burdensome hospital transfers, improve symptom treatment and control, augment supportive services, and reduce nursing home transitions for patients, and to improve caregiver outcomes of communication, shared decision-making and distress.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:55+

474 Participants Needed

AL001 for Frontotemporal Dementia

Indianapolis, Indiana
This trial is testing AL001, a drug given through an IV, to see if it can help people with a genetic mutation that causes frontotemporal dementia. The goal is to find out if AL001 can improve brain health in these individuals.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:25 - 85

110 Participants Needed

Internet Cognitive Behavioral Therapy for Depression

Indianapolis, Indiana
Depression affects one-third of intensive care unit (ICU) survivors and represents a potentially modifiable target to slow cognitive decline and reduce the risk of Alzheimer's disease and related dementias (ADRD). Our multi-PI team proposes a two-arm RCT called ADEPT-ICU (Attenuating DEPression with Internet CBT to Slow Cognitive Decline in Older ICU Survivors), which will test the efficacy of an internet CBT intervention called Good Days Ahead (GDA) to reduce the burden of subjective cognitive decline (SCD) in older ICU survivors with moderate to severe depressive symptoms after ICU hospitalization.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50+

300 Participants Needed

Diet and Exercise for High Blood Pressure

Indianapolis, Indiana
The goal of this randomized controlled trial is to determine the impact of Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) diet and aerobic training on cognition in Black adults with high systolic blood pressure. Researchers will compare Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) versus Enhanced Usual Care (EUC) to evaluate the effects on cognition. Participants will complete cognitive and cardiovascular assessments, 24-hr blood pressure monitoring, standard blood pressure measurements, weight, fingerstick for HbA1c point-of-care testing, and questionnaires. Participants may also choose to participate in an optional blood draw for DNA Repair Capacity testing as a modifiable risk factor for aging-associated diseases.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:35 - 75

128 Participants Needed

Brain Safe App for Alzheimer's Disease

Indianapolis, Indiana
This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Trial Details

Trial Status:Active Not Recruiting
Age:60+

706 Participants Needed

Continuous Glucose Monitoring for Diabetes Management in Dementia

Indianapolis, Indiana
Aim 1: Characterize shared decision-making and unmet patient-caregiver dyads needs for patients with diabetes and Alzheimer's Disease and related dementias (ADRD) while using a continuous glucose monitoring (CGM) device. Aim 2: Develop an interactive tool to enhance shared decision-making for diabetes management.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

62 Participants Needed

Atorvastatin for Preventing Dementia

Indianapolis, Indiana
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:75+

20000 Participants Needed

Why Other Patients Applied

"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

OF
Alzheimer's Disease PatientAge: 65

"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

EK
Mild Cognitive Impairment PatientAge: 72

"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

AH
Dementia PatientAge: 64

"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

WU
Healthy Volunteer PatientAge: 76

"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

VL
Alzheimer's PatientAge: 71

Sensory Stimulation for Alzheimer's Disease

Indianapolis, Indiana
This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50 - 90

670 Participants Needed

Donanemab for Early Alzheimer's Disease

Indianapolis, Indiana
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1736 Participants Needed

UPLIFT-AD for Alzheimer's Disease

Indianapolis, Indiana
The purpose of this study is to evaluate a comprehensive model for integrating both primary and specialty Palliative Care for older adults with dementia into nursing facilities. Palliative Care is a supportive care approach that aims to improve the quality of life of patients and their families facing serious or life-threatening illnesses, through the prevention and relief of suffering through the treatment of pain and other problems, using physical, psychosocial and spiritual approaches. Palliative care is specialized medical care for people who are living with a serious illness. This type of care is focused on providing relief from the symptoms and from the stress of the illness. The goal is to improve quality of life for both patient and family. The UPLIFT-AD model will include providing education on primary Palliative Care for residents with dementia to nursing facility staff, training nursing facility staff in providing primary Palliative Care, and providing access to specialty Palliative Care consultations for residents. To help understand the impact of these interventions, this study will also collect information about resident health, the care they receive, and perceptions of their quality of life according to both family members and nursing facility staff.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2000 Participants Needed

KarXT + KarX-EC for Alzheimer's Disease

Indianapolis, Indiana
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85

586 Participants Needed

ACI-24.060 for Alzheimer's Disease and Down Syndrome

Indianapolis, Indiana
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 85

140 Participants Needed

LY3954068 for Alzheimer's Disease

Indianapolis, Indiana
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. Participants will have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 85

48 Participants Needed

LY3372689 for Alzheimer's Disease

Indianapolis, Indiana
This trial is testing a new drug, LY3372689, on people with early symptoms of Alzheimer's Disease to see if it is safe and how it affects their symptoms.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60 - 85

330 Participants Needed

5-Cog Assessment for Dementia

Bloomington, Indiana
This trial tests a quick and easy memory test called 5-Cog in older adults, especially those from underserved communities. The test helps doctors find memory problems early, leading to faster treatment and better care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

6600 Participants Needed

Brain CareNotes App for Alzheimer's Disease Caregiver Burden

Bloomington, Indiana
The purpose of this study is to assess feasibility and to estimate efficacy of our app "Brain CareNotes" for dementia caregivers who reside in a rural setting (as defined by RUCA codes 4 through 10). The Brain CareNotes app is designed to reduce informal caregiver burden of those caring for individuals with Alzheimer's disease and related dementias (ADRD) and behavioral and psychological symptoms of dementia (BPSD) of individuals with ADRD. The study will enroll up to 60 rural caregivers of community-dwelling individuals living with ADRD. Caregivers will be randomized to use the Brain CareNotes app or an attention control education-only app for six months, with usage reminders.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

Mobile Telehealth for Alzheimer's Disease

Bloomington, Indiana
This study is a randomized, controlled trial (RCT) to evaluate usability and acceptability, and met and unmet needs from a caregiver intervention app, Brain CareNotes, among unpaid Hispanic caregivers of patients with dementia. Brain CareNotes provides support for management of the behavioral and psychological symptoms of dementia (BPSD) displayed by care recipients. Over 10 months, the trial will enroll 40 Hispanic caregivers of community-dwelling patients diagnosed with Alzheimer's disease or a related dementia (ADRD). Caregivers will be randomized to use the Brain CareNotes app or an attention control education-only app for 12 months, with usage reminders.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

40 Participants Needed

12

Know someone looking for new options? Spread the word

Match to a Trial